AbVir is an early-stage biotechnology company developing first-in-class antibody therapeutics against Epstein–Barr virus (EBV). Our pipeline centers on potent monoclonal antibodies that target key EBV glycoproteins and demonstrate exceptional neutralization potency and protection in rigorous preclinical humanized mouse models. With post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated conditions representing major unmet medical needs, Abvir aims to deliver the first targeted antiviral immunotherapy with both prophylactic and therapeutic potential.